MTHFR

MTHFR stands for methylenetetrahydrofolate reductase, an enzyme that handles one step in the folate cycle. Your body uses folate and other B vitamins to convert the amino acid homocysteine into methionine. When the enzyme works at full speed, homocysteine stays low. When it runs slow, homocysteine can build up, but mostly when folate or vitamin B12 is also short. The gene rarely causes trouble on its own; it amplifies a vitamin shortfall that's already there.

A test looks at the two best-known variants in this gene. The first, C677T, is a cytosine-to-thymine change at position 677 that produces a version of the enzyme with reduced activity (it's described as thermolabile, meaning it slows further at higher temperatures), and it's the variant most consistently tied to higher homocysteine. The second, A1298C, is an adenine-to-cytosine change at position 1298 with a weaker and less consistent effect. A genotype test for MTHFR looks for one or both of these, sometimes sold as an "MTHFR mutation test."

You inherit two copies of the gene, so your result is reported as a genotype rather than a number. There is no "high" or "low" reading and no reference range to land inside, which is why this page has no interpretation scale: the result is which letters you carry, not how much of anything you have.

A lab spells out your status for each variant. Reading it is easier once you know the vocabulary, because the same three patterns cover almost every report:

That last pattern is the headline most people came to read about, so the prevalence is worth saying plainly: two copies of C677T are not rare. MedlinePlus estimates that 10 to 15 percent of North American white populations and around 25 percent of Hispanic populations carry this genotype. A result that sounds alarming on a wellness website is one that millions of healthy people share without ever knowing it.

Here is the disconnect at the center of this marker. Search interest in MTHFR is enormous, and a whole supplement industry is built on it, yet the people best positioned to judge the test recommend against ordering it routinely. MedlinePlus states directly that medical experts do not recommend testing for the common MTHFR gene changes in most cases. That position rests on a 2013 American College of Medical Genetics practice guideline that found a lack of evidence supporting MTHFR polymorphism testing.

The reasoning is not mysterious. The variants are too common to flag a meaningful subgroup, their effect on homocysteine is modest unless a B vitamin is also low, and the genotype rarely changes what a clinician does next. The actionable answer almost always lives downstream, in the homocysteine level and the B vitamins feeding it, which is where the homocysteine-versus-B12 comparison starts and where workups actually begin. Knowing your genotype usually adds a label, not a plan.

Genuine reasons to look at the gene do exist; they're just narrower than the marketing implies. A provider may order it when homocysteine comes back unexpectedly high and the common nutritional causes have been checked, when a close relative was diagnosed with homocystinuria or an early venous clot, or to follow up a positive newborn screen. In those settings the genotype is a piece of a specialist's puzzle, read alongside the homocysteine level and sometimes methylmalonic acid, not a standalone verdict. Severe inherited problems of this pathway are real but rare, and they sit firmly in specialist territory rather than routine bloodwork.

For everyone else, the honest framing is the one the homocysteine workup already uses: the gene is read last, if at all. The result also lands as a cluster of cryptic codes rather than a level, so reading it starts with decoding what C677T and A1298C stand for before anything else. The MTHFR result is the certificate on the wall; homocysteine is what your body does with it.